New Merck MILLIPLEX® MAP Human Cancer Autoantibody Panel, a 15-plex customisable panel.
Being the third¹ liquid biopsy test for Biocartis, the newly launched assay, Idylla™ ctNRAS-BRAF-EGFR S492R Mutation Assay (Research Use Only), also marks an important milestone in the partnership with the leading science and technology company Merck².
Biocartis, an innovative molecular diagnostics company, today announces the launch of its second liquid biopsy assay, the Idylla™ ctKRAS Mutation Assay (Research Use Only, RUO), which was developed in partnership with the leading science and technology company Merck1 on Biocartis’ molecular diagnostics platform Idylla™.
Multiplex assays of the anti-apoptotic BCL-2 family
A hallmark of cancer cells is defects in the apoptotic cell death program.
For over ten years, Merck have offered the benefits of MILLIPLEX® map multiplexed assay panels—containing all the components and reagents you need to detect multiple analytes simultaneously.